+49 2066 50687-70

Noscendo – tHe company

About us

Noscendo GmbH is the leading global provider of software-based pathogen identification technology. We’ve made it our objective to revolutionise infection diagnostics, thus saving patient lives.

Scores of well-known university hospitals, major regional hospitals and hospital groups are already using DISQVER. We also work with several health insurance providers.

We have already received a host of awards for our pioneering approach. Noscendo was named Health-i Pioneer 2020 by Handelsblatt and Techniker Krankenkasse (TK). The award honours highly innovative ideas in the healthcare sector. In 2019, the scientific project behind DISQVER was awarded the ‘SIK Innovation Prize 2019’ by the Stuttgart Intensive Care Congress (SIK).

DISQVEr together!

Noscendo in numbers

2017

Noscendo founded

2019

Approval of DISQVER analysis platform

2

Sites, Tübingen and Duisburg

News

pressEN
Updated Duke-ISCVID Criteria for Infective Endocarditis now includes metagenomic Next-Generation-Sequencing (mNGS)

The 2023 Duke-International Society for Cardiovascular Infectious Diseases Criteria for Infective Endocarditis now includes metagenomic next-generation sequencing (mNGS) as a new, useful diagnostic tool. “The field of cardiovascular infectious diseases is witnessing a game-changing development,” says Philip Stevens, CEO of Noscendo, the world’s leading provider of software-based pathogen identification. “This is an important step towards the acceptance of this type of technology in the diagnosis of challenging infections in critically ill patients.”

pressEN
World Sepsis Day on 13th September: Study on a new, digital pathogen diagnostic tool is evaluated

At least 85,000 people die every year in Germany from Sepsis, the most severe course of an infectious disease - also known commonly as blood poisoning. World Sepsis Day on September 1 3rd draws attention to this. In the case of Sepsis, it is crucial to identify the respective pathogen early and reliably. However, the detection is often not successful with the methods commonly used today. In a maximum of 30 percent of cases, a pathogen is identified using classic blood culture, in sepsis patients who have already been treated with antibiotics often in less than 10 percent of the cases. For this reason, a German-wide project led by the Department of Anaesthesiology and Intensive Care Medicine at Essen University Hospital is investigating how patients can benefit from a new, digital method for identifying pathogens. At the beginning of August 2023, the recruitment phase of this study was completed, earlier than planned and the evaluation of the results started.

Team

Dr. Florence Awamu Ndonglack

Dr. Florence Awamu Ndonglack

Customer Success Representative

Dr. Jennifer Axnick

Dr. Jennifer Axnick

Medical Project Manager

Johannes Becher

Johannes Becher

Data Engineer

Dr. Marcus Benz

Dr. Marcus Benz

Chief Operating Officer

Dr. Daniel borda-molina

Dr. Daniel borda-molina

Bioinformatician

Julia Bottlang

Julia Bottlang

Team Lead Production

Christof Brass

Christof Brass

Head of Finance

Nico Büker

Nico Büker

Software Developer

Sebastian Clanzett

Sebastian Clanzett

Vice President Bio & Information Technology

Dr. Claudia Disque-Kochem

Dr. Claudia Disque-Kochem

Enabling Engineer

Irene Gil Farina

Irene Gil Farina

Vice President Research & Development

Michelle Fiedler

Michelle Fiedler

Technical Employee

Dr. Silke Grumaz

Dr. Silke Grumaz

Chief Scientific Officer, Co-Founder

Dr. Peter Haug

Dr. Peter Haug

Chief Strategy Officer, Co-Founder

Ian Hill

Ian Hill

Business Development Manager

Renè Hennig

Renè Hennig

Team Lead Frontend

Dr. Rafael Holzem

Dr. Rafael Holzem

Quality Management Representative

Scott G. Hopkins

Scott G. Hopkins

Sales Operations Director

Mattias Horn

Mattias Horn

Senior Solution Architect

Dr. Petra Horvatek

Dr. Petra Horvatek

Diagnostic Liaison Manager

Vanessa Huissel

Vanessa Huissel

Technician

Anne-Caroline Joly

Anne-Caroline Joly

Field Application Scientist

Thomas Kästner

Thomas Kästner

Head of IT Operations

Sabine Kießling-Parr

Sabine Kießling-Parr

Key Account Manager

Dr. Philipp Kirstahler

Dr. Philipp Kirstahler

Bioinformatician

Dr. Matthias Klaften

Dr. Matthias Klaften

Head of Real World Evidence

Michael Klomfass

Michael Klomfass

Senior IT Operator

Christina Koumourzi-Ridil

Christina Koumourzi-Ridil

Vice President People

Silas Krug

Silas Krug

Software Developer

Myriam Livrozet

Myriam Livrozet

Business Development Manager

Gabriele Magliano

Gabriele Magliano

Senior IT Operator

Dr. Sonia Mazitelli

Dr. Sonia Mazitelli

Scientist

MARKUS MOOCK

MARKUS MOOCK

Research Assistant

Dr. Andreas Moritz

Dr. Andreas Moritz

Automation Scientist

Dr. Harm Müller

Dr. Harm Müller

Key Account Manager

Ulrike Neder

Ulrike Neder

Team Lead Data Analytics

Marco Pietschmann

Marco Pietschmann

Vice President Digital Integration

Philip Pohl

Philip Pohl

Technician

Dr. med. Klaus Rensing, MBA

Dr. med. Klaus Rensing, MBA

Head of Medical Affairs D/A/CH

Joshua Richenhagen

Joshua Richenhagen

Software Developer

Johannes Ristau, PhD

Johannes Ristau, PhD

Senior Field Application Scientist

Benjamin Ruff

Benjamin Ruff

IT Technician

Jörg Schäfer

Jörg Schäfer

Requirements Engineer

Katja Siepmann

Katja Siepmann

Accountant in Finance & Controlling

Dr. Thomas Smylla

Dr. Thomas Smylla

Scientist

Franziska Stephan

Franziska Stephan

Technician

Dr. Philip Stevens

Dr. Philip Stevens

Chief Executive Officer, Co-Founder

Darren Tomlinson

Darren Tomlinson

Vice President Marketing

Dr. Sandra Unsleber

Dr. Sandra Unsleber

Scientist

Frederic Vigier

Frederic Vigier

Sales Business Development Manager

Maria Watters

Maria Watters

Chief Commercial Officer

Strategic And Scientific Advisory Board

Prof. Dr. Arndt von Haeseler

Prof. von Haeseler is Head of CIBIV (Center for Integrative Bioinformatics Vienna) at the Max Perutz Labs, where he also served as the scientific director. In 2015, von Haeseler was elected as a corresponding member in Austria of the mathematics and science class of the Austrian Academy of Sciences.

Dr. Trevor Hawkins

Dr Hawkins’ 25+ year career in healthcare has included business, academic innovation and entrepreneurship. Dr Hawkins was previously Director of the Human Genome Project for the US DOE, and has held senior executive roles at Siemens Healthcare, Philips, GE Healthcare and Amersham.

Prof. Dr. James Rothman

Prof. Rothman is a highly distinguished biochemist and Sterling Professor of Cell Biology at Yale University who was awarded the 2013 Nobel Prize in Physiology/Medicine. Prof. Rothman serves, among other positions, as Chair of the Yale School of Medicine’s Department of Cell Biology and is the Director and founder of the Nanobiology Institute on Yale’s new West Campus.

Prof. Dr. Felix Wieland

Prof. Wieland is an elected Member of the Academia Europea and the National Academy of Sciences, Leopoldina, as well as an honorary member of the Charité (Medical Faculty of Humboldt University Berlin) and is a Senior Professor for Biochemistry at Heidelberg University. Prof. Wieland’s main areas of research are Enzymology, Glycobiology and Molecular Membrane Biology, including the specificity of lipid-protein interactions.

Information for physicians

More precise diagnostics – more knowledge: Find out more about the clinical use of DISQVER!

How DISQVER works

Information for medical disciplines

Publications

News

Read more about Noscendo and DISQVER or visit us at trade fairs and conferences!

All News

Publications

Events

Press

Company

DISQVER together – get to know Noscendo!

Noscendo

Team

Advisory Board

Career